Development and validation of a composite programmatic assessment tool for HIV therapy
- PMID: 23185244
- PMCID: PMC3501505
- DOI: 10.1371/journal.pone.0047859
Development and validation of a composite programmatic assessment tool for HIV therapy
Abstract
Background: We developed and validated a new and simple metric, the Programmatic Compliance Score (PCS), based on the IAS-USA antiretroviral therapy management guidelines for HIV-infected adults, as a predictor of all-cause mortality, at a program-wide level. We hypothesized that non-compliance would be associated with the highest probability of mortality.
Methods and findings: 3543 antiretroviral-naive HIV-infected patients aged ≥19 years who initiated antiretroviral therapy between January 1, 2000 and August 31, 2009 in British Columbia (BC), Canada, were followed until August 31, 2010. The PCS is composed by six non-performance indicators based on the IAS-USA guidelines: (1) having <3 CD4 count tests in the first year after starting antiretroviral therapy; (2) having <3 plasma viral load tests in the first year after starting antiretroviral therapy; (3) not having drug resistance testing done prior to starting antiretroviral therapy; (4) starting on a non-recommended antiretroviral therapy regimen; (5) starting therapy with CD4 <200 cells/mm(3); and (6) not achieving viral suppression within 6 months since antiretroviral therapy initiation. The sum of these six indicators was used to develop the PCS score - higher score indicates poorer performance. The main outcome was all-cause mortality. Each PCS component was independently associated with mortality. In the mortality analysis, the odds ratio (OR) for PCS ≥4 versus 0 was 22.37 (95% CI 10.46-47.84).
Conclusions: PCS was strongly associated with all-cause mortality. These results lend independent validation to the IAS-USA treatment guidelines for HIV-infected adults. Further efforts are warranted to enhance the PCS as a means to further improve clinical outcomes. These should be specifically evaluated and targeted at healthcare providers and patients.
Conflict of interest statement
Figures
Similar articles
-
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010).PLoS One. 2014 Mar 18;9(3):e92334. doi: 10.1371/journal.pone.0092334. eCollection 2014. PLoS One. 2014. PMID: 24642949 Free PMC article.
-
Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy.HIV Med. 2017 Mar;18(3):151-160. doi: 10.1111/hiv.12409. Epub 2016 Jul 6. HIV Med. 2017. PMID: 27385643
-
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.Antivir Ther. 2004 Oct;9(5):713-9. Antivir Ther. 2004. PMID: 15535408
-
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Lancet. 2009. PMID: 19361855 Free PMC article. Review.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
Cited by
-
Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.Lancet HIV. 2016 May;3(5):e231-8. doi: 10.1016/S2352-3018(16)00046-1. Epub 2016 Apr 7. Lancet HIV. 2016. PMID: 27126490 Free PMC article.
-
Precarious Housing Associated with Unsuppressed Viral load, sub-optimal Access to HIV Treatment and Unmet Health care Needs, Among Women Living with HIV in Metro Vancouver, Canada.AIDS Behav. 2023 Jul;27(7):2271-2284. doi: 10.1007/s10461-022-03957-2. Epub 2023 Feb 2. AIDS Behav. 2023. PMID: 36729293 Free PMC article.
-
The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.Lancet Infect Dis. 2014 Jan;14(1):40-49. doi: 10.1016/S1473-3099(13)70254-8. Epub 2013 Sep 27. Lancet Infect Dis. 2014. PMID: 24076277 Free PMC article.
-
Estimation of time of HIV seroconversion using a modified CD4 depletion model.PLoS One. 2021 Feb 12;16(2):e0246135. doi: 10.1371/journal.pone.0246135. eCollection 2021. PLoS One. 2021. PMID: 33577551 Free PMC article.
-
Process monitoring of an HIV treatment as prevention program in British Columbia, Canada.J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):e94-e109. doi: 10.1097/QAI.0000000000000293. J Acquir Immune Defic Syndr. 2014. PMID: 25072608 Free PMC article.
References
-
- Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al. (1996) Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 276: 146–154. - PubMed
-
- Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al. (1997) Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 277: 1962–1969. - PubMed
-
- Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al. (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280: 78–86. - PubMed
-
- Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et al. (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283: 381–390. - PubMed
-
- Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, et al. (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288: 222–235. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials